GeoVax Labs Launches $1 Million At-the-Market Direct Offering Under Nasdaq Rules
GeoVax Labs filed a $1 million registered direct offering priced at-the-market under Nasdaq rules to sell newly issued common shares. Proceeds will bolster cash reserves but dilute existing shareholders, potentially impacting per-share valuation and extending funding runway for its vaccine development programs.
1. Direct Offering Details
GeoVax filed a prospectus supplement for a $1 million registered direct offering under Nasdaq Listing Rule 416(k), enabling sale of newly issued common shares at prevailing market prices through an at-the-market facility. The offering allows immediate execution at current trading levels without a fixed share price or share cap, providing flexibility in raising capital.
2. Dilution and Cash Runway Implications
Net proceeds are earmarked to support ongoing vaccine development programs, enhance working capital and fund general corporate purposes. While at-the-market issuance can extend cash runway more rapidly than a fixed-price deal, it increases share count and may dilute existing shareholders, affecting earnings per share and valuation metrics.